Abstract:RAF and MEK inhibitors greatly benefit BRAF-mutant melanoma patients, but eventually, nearly 80% of patients relapse. Reactivation of MAPK signaling and activation of PI3K/AKT signaling play a major role in the development of targeted therapy resistance. Therefore, understanding how tumor cells regulate these signaling pathways may yield new insights into drug resistance. The small GTPase ARF6, a member of the RAS superfamily, influences oncogenic signaling by controlling cytoskeletal rearrangements and through endomembrane trafficking. We previously reported that ARF6 is aberrantly activated in metastatic melanoma and that activation of ARF6 is sufficient to promote invasion and accelerate spontaneous metastasis in vivo through WNT5A/beta-catenin and PI3K/AKT signaling. In contrast to ARF6 activation, herein we show that tumor-specific deletion of Arf6 significantly limits development and progression of BRAFV600E melanoma in vivo. Mechanistically, we discovered these ARF6-dependent phenotypes may be attributed to a previously unknown role for ARF6 in augmenting BRAFV600E and PI3K protein levels. Specifically, pharmacologic or genetic activation ARF6 (ARF6-GTP) is sufficient to increase BRAFV600E and PI3K protein levels in both murine and human melanoma. As a result, ARF6-GTP is also sufficient to enhance activation of MEK, ERK and AKT. Importantly, murine tumors expressing constitutively active ARF6 (ARF6Q67L) show increased expression of anti-apoptotic proteins compared to ARF6WT tumors. Together these data suggest that ARF6 promotes tumor survival through augmentation of the BRAF/MAPK and PI3K/AKT pathways. To test this, we pharmacologically activated ARF6 during serum withdrawal or vemurafenib treatment. In both conditions, ARF6 activation is sufficient to prevent apoptosis. Surprisingly, we found that vemurafenib treatment leads to ARF6 activation, suggesting that ARF6 may be an important component of the cellular machinery that reactivates MAPK signaling after RAF inhibition. Indeed, pharmacologic activation of ARF6 maintains MAPK signaling (pERK levels) in the presence of vemurafenib and enhances pERK and pAKT-mediated suppression of apoptotic signaling. In summary, our data suggest that in addition to well-established roles in tumor cell invasion, ARF6 is a crucial mediator of survival during tumor progression and in the context of BRAF targeted therapy. More work is needed to understand how ARF6 activation increases BRAF and PI3K expression and if ARF6 activation contributes to the development of persister cells in melanoma. Citation Format: Junhua Wang, Coulson Rich, Aaron Rogers, Sheri Holmen, Roger Wolff, Allie Grossmann. The small GTPase ARF6 augments BRAF and PI3K expression to promote melanoma survival [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 1997.

K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling

Mtorc1/autophagy-Regulated MerTK in Mutant BRAFV600 Melanoma with Acquired Resistance to BRAF Inhibition

Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAF-mediated signaling

Acetylation-dependent regulation of BRAF oncogenic function

Mir‐200c/bmi1 Axis and Epithelial–mesenchymal Transition Contribute to Acquired Resistance to BRAF Inhibitor Treatment

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma

MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways.

141 Targeting TGFβ Signaling in BRAF Mutant Melanoma

Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins

LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway

eIF4F controls ERK MAPK signaling in melanomas with BRAF and NRAS mutations

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Deletion of IKKβ in activated fibroblasts promotes tumor progression in melanoma

Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling

Proteostatic reactivation of the developmental transcription factor TBX3 drives BRAF/MAPK-mediated tumorigenesis

IRE1α-XBP1 Pathway Promotes Melanoma Progression by Regulating IL-6/STAT3 Signaling

MITF activity is regulated by a direct interaction with RAF proteins in melanoma cells

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.

Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2

Abstract 1997: The small GTPase ARF6 augments BRAF and PI3K expression to promote melanoma survival